135 related articles for article (PubMed ID: 14963281)
1. Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction.
Bruno A; McConnell JP; Cohen SN; Tietjen GE; Wallis RA; Gorelick PB; Bang NU
Stroke; 2004 Mar; 35(3):727-30. PubMed ID: 14963281
[TBL] [Abstract][Full Text] [Related]
2. Aspirin and urinary 11-dehydrothromboxane B(2) in African American stroke patients.
Bruno A; McConnell JP; Mansbach HH; Cohen SN; Tietjen GE; Bang NU
Stroke; 2002 Jan; 33(1):57-60. PubMed ID: 11779889
[TBL] [Abstract][Full Text] [Related]
3. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events.
Thomson VS; John B; George P; Joseph G; Jose J
J Postgrad Med; 2009; 55(4):252-6. PubMed ID: 20083870
[TBL] [Abstract][Full Text] [Related]
4. Comparison of aspirin response measured by urinary 11-dehydrothromboxane B2 and VerifyNow aspirin assay in patients with ischemic stroke.
Dharmasaroja PA; Sae-Lim S
J Stroke Cerebrovasc Dis; 2014; 23(5):953-7. PubMed ID: 24126290
[TBL] [Abstract][Full Text] [Related]
5. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.
Eikelboom JW; Hirsh J; Weitz JI; Johnston M; Yi Q; Yusuf S
Circulation; 2002 Apr; 105(14):1650-5. PubMed ID: 11940542
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
7. Association of recurrent cerebral infarction with adenosine diphosphate- and collagen-induced platelet aggregation in patients treated with ticlopidine and/or aspirin.
Abumiya T; Houkin K
J Stroke Cerebrovasc Dis; 2011; 20(4):319-23. PubMed ID: 20634093
[TBL] [Abstract][Full Text] [Related]
8. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
Byrne A; Moran N; Maher M; Walsh N; Crean P; Fitzgerald DJ
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3224-9. PubMed ID: 9409315
[TBL] [Abstract][Full Text] [Related]
9. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.
Gorelick PB; Richardson D; Kelly M; Ruland S; Hung E; Harris Y; Kittner S; Leurgans S;
JAMA; 2003 Jun; 289(22):2947-57. PubMed ID: 12799402
[TBL] [Abstract][Full Text] [Related]
10. Aspirin dosage and thromboxane synthesis in patients with vascular disease.
Hart RG; Leonard AD; Talbert RL; Pearce LA; Cornell E; Bovill E; Feinberg WM
Pharmacotherapy; 2003 May; 23(5):579-84. PubMed ID: 12741431
[TBL] [Abstract][Full Text] [Related]
11. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
[TBL] [Abstract][Full Text] [Related]
12. Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction.
Uyama O; Shimizu S; Nakanishi T; Nakahama H; Takiguchi A; Hayashi Y; Yamamoto S; Sugita M
Intern Med; 1992 Jun; 31(6):735-9. PubMed ID: 1392173
[TBL] [Abstract][Full Text] [Related]
13. Differential Impact of Serial Measurement of Nonplatelet Thromboxane Generation on Long-Term Outcome After Cardiac Surgery.
Kakouros N; Gluckman TJ; Conte JV; Kickler TS; Laws K; Barton BA; Rade JJ
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29097390
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of urinary 11-dehydro-thromboxane B
Vasudevan A; Tecson KM; Bennett-Firmin J; Bottiglieri T; Lopez LR; Peterson M; Sathyamoorthy M; Schiffmann R; Schussler JM; Swift C; Velasco CE; McCullough PA
Catheter Cardiovasc Interv; 2018 Oct; 92(4):653-658. PubMed ID: 29193683
[TBL] [Abstract][Full Text] [Related]
15. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Maree AO; Fitzgerald DJ
Circulation; 2007 Apr; 115(16):2196-207. PubMed ID: 17452618
[No Abstract] [Full Text] [Related]
16. Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease.
Liu T; Zhang J; Chen X; Feng X; Fu SW; McCaffrey TA; Liu M
Gene; 2015 Oct; 571(1):23-7. PubMed ID: 26095809
[TBL] [Abstract][Full Text] [Related]
17. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
18. Resistance to low-dose aspirin therapy among patients with acute coronary syndrome in relation to associated risk factors.
Salama MM; Morad AR; Saleh MA; Sabri NA; Zaki MM; ElSafady LA
J Clin Pharm Ther; 2012 Dec; 37(6):630-6. PubMed ID: 23121257
[TBL] [Abstract][Full Text] [Related]
19. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane.
Carroll RC; Craft RM; Snider CC; Aligeti VR; Wortham DC
Anesth Analg; 2013 Feb; 116(2):282-6. PubMed ID: 23302970
[TBL] [Abstract][Full Text] [Related]
20. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.
Matías-Guiu J; Ferro JM; Alvarez-Sabín J; Torres F; Jiménez MD; Lago A; Melo T;
Stroke; 2003 Apr; 34(4):840-8. PubMed ID: 12649515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
